Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.70
- Piotroski Score 3.00
- Grade Buy
- Symbol (RNAC)
- Company Cartesian Therapeutics, Inc.
- Price $18.75
- Changes Percentage (8.19%)
- Change $1.42
- Day Low $16.37
- Day High $18.80
- Year High $42.60
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $43.00
- High Stock Price Target $45.00
- Low Stock Price Target $40.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-219,710,000
Income Statement
Quarterly
Annual
Latest News of RNAC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Steve Kornacki: The key voter shifts that led to Trump's battleground state sweep
Trump made significant gains with rural and blue-collar voters in key states, eroding Democratic support. In Arizona, new Hispanic and Native American support helped him reclaim Maricopa County. In Ge...
By NBC News | 1 day ago -
Alejandro Garnacho's unusual goal reaction explained by Man United captain Bruno Fernandes
Manchester United's Alejandro Garnacho scored a stunning goal against Leicester but didn't celebrate, believing some fans lost faith. Captain Bruno Fernandes encouraged him to embrace his success, pra...
By AP NEWS | 1 week ago -
How can Ruben Amorim and Man Utd get the best out of Alejandro Garnacho?
Alejandro Garnacho's rise from occasional starter to a key player for Manchester United is remarkable. Despite occasional mistakes, his impact on games is significant, making him a top scorer. Garnach...
By The New York Times | 1 week ago
